ATAI
Price:
$4.4
Market Cap:
$829.95M
Atai Beckley NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Amstelveen, Netherlands.
Industry
Medical - Pharmaceuticals
IPO Date
2021-06-18
Stock Exchange
NASDAQ
Ticker
ATAI
According to Atai Beckley N.V’s latest financial reports and current stock price. The company's current ROE is -107.86%. This represents a change of 297.98% compared to the average of -27.10% of the last 4 quarters.
The mean historical ROE of Atai Beckley N.V over the last ten years is -62.75%. The current -107.86% ROE has changed 71.88% with respect to the historical average. Over the past ten years (40 quarters), ATAI's ROE was at its highest in in the March 2020 quarter at 27.27%. The ROE was at its lowest in in the December 2020 quarter at -95.34%.
Average
-62.75%
Median
-44.71%
Minimum
-128.35%
Maximum
-16.56%
Discovering the peaks and valleys of Atai Beckley N.V ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 675.27%
Maximum Annual ROE = -16.56%
Minimum Annual Increase = -69.47%
Minimum Annual ROE = -128.35%
| Year | ROE | Change |
|---|---|---|
| 2024 | -128.35% | 675.27% |
| 2023 | -16.56% | -69.47% |
| 2022 | -54.23% | 54.14% |
| 2021 | -35.18% | -68.71% |
| 2020 | -112.44% | 277.99% |
The current ROE of Atai Beckley N.V (ATAI) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-66.38%
5-year avg
-69.35%
10-year avg
-62.75%
Atai Beckley N.V’s ROE is greater than Nektar Therapeutics (-356.81%), greater than Inhibrx Biosciences, Inc. (-186.06%), greater than Enliven Therapeutics, Inc. (-29.15%), greater than Dianthus Therapeutics, Inc. (-33.02%), greater than ORIC Pharmaceuticals, Inc. (-45.33%), greater than Syndax Pharmaceuticals, Inc. (-160.60%), greater than Relay Therapeutics, Inc. (-42.94%), greater than Amylyx Pharmaceuticals, Inc. (-68.95%), greater than Immatics N.V. (-23.26%), greater than Sana Biotechnology, Inc. (-115.33%),
| Company | ROE | Market cap |
|---|---|---|
| -356.81% | $1.17B | |
| -186.06% | $1.27B | |
| -29.15% | $1.27B | |
| -33.02% | $1.62B | |
| -45.33% | $1.11B | |
| -160.60% | $1.71B | |
| -42.94% | $1.39B | |
| -68.95% | $1.20B | |
| -23.26% | $1.44B | |
| -115.33% | $1.38B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Atai Beckley N.V using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Atai Beckley N.V or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Atai Beckley N.V's ROE?
How is the ROE calculated for Atai Beckley N.V (ATAI)?
What is the highest ROE for Atai Beckley N.V (ATAI)?
What is the 3-year average ROE for Atai Beckley N.V (ATAI)?
What is the 5-year average ROE for Atai Beckley N.V (ATAI)?
How does the current ROE for Atai Beckley N.V (ATAI) compare to its historical average?